Sarah Hull1, Marcella Attanasio2, Gavin Arno1, Keren Carss3, Anthony G Robson1, Dorothy A Thompson4, Vincent Plagnol5, Michel Michaelides1, Graham E Holder1, Robert H Henderson6, F Lucy Raymond7, Anthony T Moore8, Andrew R Webster1. 1. Moorfields Eye Hospital, London, England2University College London Institute of Ophthalmology, London, England. 2. Moorfields Eye Hospital, London, England3L'Unità Operativa di Oculistica, Ospedale Sacrocuore-Don Calabria, Negrar, Italy. 3. Department of Haematology, University of Cambridge, Cambridge, England5National Institute for Health Research (NIHR) BioResource-Rare Diseases, Cambridge University Hospitals, Cambridge Biomedical Campus, Cambridge, England. 4. Department of Ophthalmology, Great Ormond Street Hospital for Children, London, England. 5. University College London Genetics Institute, London, England. 6. Moorfields Eye Hospital, London, England6Department of Ophthalmology, Great Ormond Street Hospital for Children, London, England. 7. National Institute for Health Research (NIHR) BioResource-Rare Diseases, Cambridge University Hospitals, Cambridge Biomedical Campus, Cambridge, England8Department of Medical Genetics, Cambridge Institute for Medical Research, University of Cambridge, Cambridge, England. 8. Moorfields Eye Hospital, London, England2University College London Institute of Ophthalmology, London, England9Ophthalmology Department, University of California, San Francisco Medical School, San Francisco.
Abstract
IMPORTANCE: There are limited published data on the phenotype of retinitis pigmentosa (RP) related to CNGB1 variants. These data are needed both for prognostic counseling of patients and for understanding potential treatment windows. OBJECTIVE: To describe the detailed clinical and molecular genetic findings in a series of patients with RP with likely pathogenic variants in CNGB1. DESIGN, SETTING, AND PARTICIPANTS: In this case series, 10 patients from 9 families underwent full ophthalmologic examination. Molecular investigations included whole-exome analysis in 6 patients. The study was conducted from April 17, 2013, to March 3, 2016, with final follow-up completed on March 2, 2016, and data were analyzed from October 27, 2014, to March 29, 2016. MAIN OUTCOMES AND MEASURES: Results of ophthalmologic examination and molecular genetic analysis of CNGB1. RESULTS: In this case series, 7 women and 3 men from 9 families with a mean (SD) age of 47.4 (13.2) years identified as having CNGB1 variants were included in this study; there was a mean (SD) follow-up length of 3.7 (2.8) years. The first clinical presentation was with nyctalopia in childhood with visual field loss documented later at a mean (SD) age of 33.2 (8.0) years. All patients had preserved best-corrected visual acuity into adulthood, with a mean of 0.1 logMAR (Snellen equivalent, 20/25) in each eye (logMAR range, 0.0 to 0.3 [Snellen 20/20 to 20/40] in the right eye and -0.1 to 0.3 [Snellen 20/16 to 20/40] in the left eye). Fundus examination revealed midperipheral retinal pigment epithelial atrophy and intraretinal pigment migration. Optical coherence tomography of the macula demonstrated complete preservation of the inner segment ellipsoid band in 1 patient, with variable lateral extent in the other patients corresponding to the diameter of a paracentral ring of increased fundus autofluorescence. Electrophysiologic testing in 6 patients confirmed a rod-cone dystrophy phenotype. Molecular investigations identified a previously reported missense variant (p.[N986I]) and 7 variants not previously reported in disease including 4 nonsense (p.[(Q88*], p.[Q222*], p.[Q318*], and p.[R729*]), 2 frameshift (p.[A1048fs*13], p.[L849Afs*3]), and a splice site variant (c.761 + 2T>A). CONCLUSIONS AND RELEVANCE: The data from this study suggest that visual acuity and foveal structure in patients with RP are preserved into adult life such that a lengthy window of opportunity should exist for intervention with novel therapies.
IMPORTANCE: There are limited published data on the phenotype of retinitis pigmentosa (RP) related to CNGB1 variants. These data are needed both for prognostic counseling of patients and for understanding potential treatment windows. OBJECTIVE: To describe the detailed clinical and molecular genetic findings in a series of patients with RP with likely pathogenic variants in CNGB1. DESIGN, SETTING, AND PARTICIPANTS: In this case series, 10 patients from 9 families underwent full ophthalmologic examination. Molecular investigations included whole-exome analysis in 6 patients. The study was conducted from April 17, 2013, to March 3, 2016, with final follow-up completed on March 2, 2016, and data were analyzed from October 27, 2014, to March 29, 2016. MAIN OUTCOMES AND MEASURES: Results of ophthalmologic examination and molecular genetic analysis of CNGB1. RESULTS: In this case series, 7 women and 3 men from 9 families with a mean (SD) age of 47.4 (13.2) years identified as having CNGB1 variants were included in this study; there was a mean (SD) follow-up length of 3.7 (2.8) years. The first clinical presentation was with nyctalopia in childhood with visual field loss documented later at a mean (SD) age of 33.2 (8.0) years. All patients had preserved best-corrected visual acuity into adulthood, with a mean of 0.1 logMAR (Snellen equivalent, 20/25) in each eye (logMAR range, 0.0 to 0.3 [Snellen 20/20 to 20/40] in the right eye and -0.1 to 0.3 [Snellen 20/16 to 20/40] in the left eye). Fundus examination revealed midperipheral retinal pigment epithelial atrophy and intraretinal pigment migration. Optical coherence tomography of the macula demonstrated complete preservation of the inner segment ellipsoid band in 1 patient, with variable lateral extent in the other patients corresponding to the diameter of a paracentral ring of increased fundus autofluorescence. Electrophysiologic testing in 6 patients confirmed a rod-cone dystrophy phenotype. Molecular investigations identified a previously reported missense variant (p.[N986I]) and 7 variants not previously reported in disease including 4 nonsense (p.[(Q88*], p.[Q222*], p.[Q318*], and p.[R729*]), 2 frameshift (p.[A1048fs*13], p.[L849Afs*3]), and a splice site variant (c.761 + 2T>A). CONCLUSIONS AND RELEVANCE: The data from this study suggest that visual acuity and foveal structure in patients with RP are preserved into adult life such that a lengthy window of opportunity should exist for intervention with novel therapies.
Authors: Peter Charbel Issa; Peggy Reuter; Laura Kühlewein; Johannes Birtel; Martin Gliem; Anke Tropitzsch; Katherine L Whitcroft; Hanno J Bolz; Kenji Ishihara; Robert E MacLaren; Susan M Downes; Akio Oishi; Eberhart Zrenner; Susanne Kohl; Thomas Hummel Journal: JAMA Ophthalmol Date: 2018-07-01 Impact factor: 7.389
Authors: Johanna E Wagner; Lena Zobel; Maximilian J Gerhardt; Catherine R O'Riordan; Amy Frederick; Simon M Petersen-Jones; Martin Biel; Stylianos Michalakis Journal: Hum Gene Ther Date: 2021-09-20 Impact factor: 4.793
Authors: Bojana Radojevic; Kaylie Jones; Martin Klein; Margarita Mauro-Herrera; Ronald Kingsley; David G Birch; Lea D Bennett Journal: Ophthalmic Genet Date: 2020-10-14 Impact factor: 1.803
Authors: Marco Nassisi; Vasily M Smirnov; Cyntia Solis Hernandez; Saddek Mohand-Saïd; Christel Condroyer; Aline Antonio; Laura Kühlewein; Melanie Kempf; Susanne Kohl; Bernd Wissinger; Fadi Nasser; Sara D Ragi; Nan-Kai Wang; Janet R Sparrow; Vivienne C Greenstein; Stylianos Michalakis; Omar A Mahroo; Rola Ba-Abbad; Michel Michaelides; Andrew R Webster; Simona Degli Esposti; Brooke Saffren; Jenina Capasso; Alex Levin; William W Hauswirth; Claire-Marie Dhaenens; Sabine Defoort-Dhellemmes; Stephen H Tsang; Eberhart Zrenner; Jose-Alain Sahel; Simon M Petersen-Jones; Christina Zeitz; Isabelle Audo Journal: Hum Mutat Date: 2021-05-16 Impact factor: 4.700
Authors: Simon M Petersen-Jones; Laurence M Occelli; Paige A Winkler; Winston Lee; Janet R Sparrow; Mai Tsukikawa; Sanford L Boye; Vince Chiodo; Jenina E Capasso; Elvir Becirovic; Christian Schön; Mathias W Seeliger; Alex V Levin; Stylianos Michalakis; William W Hauswirth; Stephen H Tsang Journal: J Clin Invest Date: 2017-11-20 Impact factor: 14.808
Authors: Rola Ba-Abbad; Graham E Holder; Anthony G Robson; Magella M Neveu; Naushin Waseem; Gavin Arno; Andrew R Webster Journal: Am J Ophthalmol Case Rep Date: 2019-03-19